Drug Profile
Research programme: chronic obstructive pulmonary disease therapeutics - Galapagos
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Galapagos NV
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- No development reported Chronic obstructive pulmonary disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Chronic-obstructive-pulmonary-disease in Belgium
- 08 Mar 2013 Research programme: chronic obstructive pulmonary disease therapeutics - Galapagos/Roche is available for licensing as of 08 Mar 2013. http://www.glpg.com
- 08 Mar 2013 The alliance between Galapagos and Roche in both Chronic obstructive pulmonary disease and Fibrosis has been ended